Pas de connexion internet — affichage de la version enregistrée de la page.

Aclaris Therapeut…

USUSD
← Vers le Screener
US:ACRSLSE:0H8T

Aclaris Therapeutics Inc (US:ACRS) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site Web
aclaristx.com
Relations avec les Investisseurs
investor.aclaristx.com/
Secteur
Health Care · Biotechnology: Pharmaceutical Preparations
Siège Social
WAYNE, United States
PDG
Neal S. Walker
Employés
69
Actions en Circulation
147.2 M au 2026-07-31
Flottant
101.17 M
Capitalisation Boursière
563.77 M USD
Initiés
2.18%
Investisseurs Institutionnels
84%
Secteur d'Activité (SIC)
Pharmaceutical Preparations
FCF
−62.2 M USD
Dette
10.7 M USD
trésorerie nette
Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
Description

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Bourses et Tickers

BourseTickerDevisePrixType
US USA StocksACRS principaleUSD3.83 +1.06%actions ordinaires
LSE London Stock Exchange0H8T IOBUSD4.34 +0.00%actions ordinaires

Cours sur 3 Mois

jour de hausse jour de baisseSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas
publicité

Principaux Actionnaires

DétenteurParticipationActionsDate du Rapport
RA Capital Management, L…9.1%12.72 M2026-06-30
BML Capital Management,…8.56%11.98 M2026-06-30
Blackrock Inc.7.18%10.04 M2026-06-30
Deep Track Capital, Lp6.68%9.35 M2026-06-30
Vivo Capital, LLC4.79%6.69 M2026-06-30
Vanguard Capital Managem…4.16%5.82 M2026-06-30
Frazier Life Sciences Ma…3.52%4.93 M2026-06-30
Rock Springs Capital Man…3.1%4.33 M2026-06-30
VANGUARD INDEX FUNDS-Van…3.03%4.24 M2026-06-30
Adage Capital Partners G…2.91%4.07 M2026-06-30
Decheng Capital LLC2.89%4.04 M2026-06-30
iShares Trust-iShares Ru…2.18%3.05 M2026-08-31
Fidelity Advisor Series…1.27%1.78 M2026-08-31
WALKER NEAL (Chief Execu…≈1.1%1.54 M2026-02-03
VANGUARD INDEX FUNDS-Van…1.04%1.45 M2026-06-30
Fidelity Salem Street Tr…0.93%1.3 M2026-07-31
SPDR SERIES TRUST-State…0.71%986 2202026-08-31
iShares Trust-iShares Ru…0.69%968 1472026-08-31
Fidelity Covington Trust…0.6%834 4402026-09-30
iShares Trust-iShares Bi…0.59%822 0912026-08-31
Fidelity Select Portfoli…0.55%774 7182026-08-31
MEHRA ANAND M.D. (Direct…≈0.52%726 4032026-06-05
Fidelity Concord Street…0.44%621 9412026-07-31
VANGUARD SCOTTSDALE FUND…0.34%472 2492026-05-31
SCHIFF ANDREW N (Directo…≈0.33%459 9952026-06-05
MONAHAN JOSEPH B (Office…≈0.19%265 8552025-02-28
LOEROP JAMES (Officer)≈0.14%192 2602026-02-03
BALTHASER KEVIN J (Chief…≈0.13%187 4532026-02-27
MOLINEAUX CHRISTOPHER P…≈0.05%69 5362026-06-05
DAVIS HUGH M. (President…≈0.03%45 4252026-02-03
HUMPHRIES WILLIAM DOUGLA…≈0.03%45 1052026-06-05
LEONARD BRADEN MICHAEL (…——2026-04-23